Wilsons Sticks to Its Buy Rating for Telix Pharmaceuticals Ltd. (TLPPF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2025
0mins
Source: Business Insider
Analyst Ratings: Shane Storey from Wilsons has maintained a Buy rating on Telix Pharmaceuticals Ltd. with a price target of A$35.00, while the stock currently trades at $18.15. The analyst consensus for the company is a Strong Buy with a price target of $21.38.
Company Performance: Telix Pharmaceuticals has seen a one-year high of $24.85 and a low of $7.78, and it has an average trading volume of 4,571 shares.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
